Peramivir

In the clinical diagnosis and treatment of influenza A and influenza B, neuraminidase inhibitors are the core category of antiviral therapies. As the only intravenously administered drug in this category, peramivir selectively inhibits the activity of influenza virus neuraminidase, thereby blocking the release and spread of the virus from infected host cells. Compared with oral anti-influenza drugs, its characteristic of no requirement for gastrointestinal absorption makes it particularly suitable for severe influenza patients, people who cannot receive oral administration, and elderly influenza patients with dysphagia. At present, it has been listed as a recommended drug for severe cases in the influenza diagnosis and treatment guidelines of many countries.

The seasonal epidemics and irregular outbreaks of influenza support the market demand for peramivir. Relevant data show that the market size of anti-influenza drugs at the terminal of domestic public medical institutions exceeded 12 billion yuan in 2023, among which neuraminidase inhibitors accounted for more than 65%, and the compound annual growth rate of peramivir has maintained at around 18% in recent years. At present, the domestic market is dominated by generic drug supply. More than 10 enterprises have obtained the production approval documents for preparations, and the localization rate of API exceeds 90%. In the provincial centralized volume-based procurement of pharmaceuticals in recent years, the winning bid price of peramivir preparations has dropped by about 72% compared with the peak price of the original research drug, further improving its clinical accessibility.

The original research enterprise of peramivir is Shionogi & Co., Ltd. of Japan, and the original trade name is Rapiacta. The core compound patent of peramivir expired in 2018 in major markets such as Japan and the United States, and the compound patent in China expired in 2021. The main dosage form approved for the original research product is injection, with specifications including 150mg/15ml and 300mg/30ml, which have been included in the Catalogue of Marketed Drugs in China as reference preparations. As of now, there are 22 pieces of peramivir API registration information on the CDE API registration platform, among which 16 are in status A (approved for use in marketed preparations). A variety of preparation products including injections and freeze-dried powder injections have been approved for marketing in China. (Data as of October 2024, please refer to the official website of CDE for the latest information.)

CATO can provide a full set of impurity reference standards for peramivir API, most of which are in stock. Orders for in-stock products placed before 16:00 will be shipped on the same day. All reference standards comply with the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can fully meet the various needs of pharmaceutical enterprises in the stages of R&D, quality control and registration declaration.